Comparative Pharmacology
Head-to-head clinical analysis: METHYCLOTHIAZIDE AND DESERPIDINE versus TRICHLOREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYCLOTHIAZIDE AND DESERPIDINE versus TRICHLOREX.
METHYCLOTHIAZIDE AND DESERPIDINE vs TRICHLOREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
Trichlorex is a thiazide-like diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
Oral: 500 mg once daily after the evening meal; sustained-release: 500 mg once daily at bedtime.
None Documented
None Documented
Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing.
Terminal elimination half-life is 8-12 hours in adults; prolonged to 20-30 hours in severe renal impairment (creatinine clearance <30 mL/min).
Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%).
Renal (90% as unchanged drug, 10% as trichloroacetic acid and trichloroethanol); minor biliary/fecal (less than 1%).
Category C
Category C
Thiazide Diuretic and Antihypertensive
Thiazide Diuretic